Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts
global health in epidemic proportions, and the resulting morbidity, mortality and economic …

Background Nonalcoholic fatty disease (NAFLD) is the most common liver disease, since it
is strongly associated with obesity and metabolic syndrome pandemics. NAFLD may affect …

Drug-induced liver injury (DILI) is a common and underestimated cause of liver disease.
Several drugs and other xenobiotics can be the cause of different clinicopathologic patterns …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …

Metabolic dysfunction–associated fatty liver disease (MAFLD) is nowadays considered the
liver manifestation of metabolic syndrome. Its prevalence is increasing worldwide in parallel …

Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is
rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 …

Obesity is commonly associated with nonalcoholic fatty liver (NAFL), a benign condition
characterized by hepatic lipid accumulation. However, NAFL can progress in some patients …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from
nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common
liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on …

Metabolic-associated fatty liver disease (MAFLD), which is often linked to obesity,
encompasses a large spectrum of hepatic lesions, including simple fatty liver …